Author

Drew Lazenby

University of MiamiORCID 0009-0004-7120-1237Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Approach:wet-lab / biochemical assay· 1

Frequent Co-Authors

Abdessamad Youssfi AlaouiiD· 1 shared Alexa Marie BarrosoiD· 1 shared Alexandra Marie CarboneiD· 1 shared Alicia Bilbao MartineziD· 1 shared Austin Daniel NewsamiD· 1 shared Daniel BilbaoiD· 1 shared Dhanvantri ChahariD· 1 shared Francesco MauraiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Abdessamad Youssfi AlaouiORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

NRF2 translation block by inhibition of cap-dependent initiation sensitizes lymphoma cells to ferroptosis and CAR-T immunotherapy

Paola Manara, Austin Daniel Newsam, Venu Venkatarame Gowda Saralamma, Tyler Andrew Cunningham, Drew Lazenby, J.J.David Ho, Marco Vincenzo Russo, Abdessamad Youssfi Alaoui, Dhanvantri Chahar, Alicia Bilbao Martinez, Nikolai S. Fattakhov, Alexandra Marie Carbone, Olivia Barbara Farag, Alexa Marie Barroso, Kyle S. Hoffman, , Jonathan Harry Schatz

This study shows that inhibiting cap-dependent translation in lymphoma cells increases sensitivity to ferroptosis and CAR-T therapy by reducing NRF2 expression.

Cancer Research · Jul 31, 2025Peer-reviewedCancer Biology